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Previously we found that passive transfer of monoclonal antibodies (MAbs) specific to either the vaccinia virus (VACV) L1R
or A33R gene product protected mice from challenge with VACV. The L1R-specific MAbs, which bind the intracellular mature
virion (IMV), neutralized virus in cell culture, whereas the A33R-specific MAbs, which bind extracellular enveloped virions
(EEV), did not. To investigate whether a protective response could be generated by vaccination with these genes, we
constructed and evaluated DNA vaccines expressing the VACV L1R and/or A33R genes under control of a cytomegalovirus
promoter. Mice were vaccinated with DNA-coated gold beads by using a gene gun and then challenged with VACV (strain WR)
intraperitoneally. Mice vaccinated with L1R alone developed neutralizing antibodies and were partially protected. Mice
vaccinated with a combination of both genes loaded on the same gold beads developed a robust anti-A33R response;
however, no neutralizing antibody response was detected, and the mice were not protected. In contrast, when mice were
vaccinated with L1R and A33R loaded on different gold beads, neutralizing (presumably anti-L1R) and anti-A33R antibody
responses were detected, and protection was markedly improved. Our results indicated that vaccination with both L1R and
A33R proteins, intended to evoke mechanistically distinct and complementary forms of protection, was more effective than
vaccination with either protein by itself. © 2000 Academic PressINTRODUCTION
Viruses in the family Poxviridae, including vaccinia
virus (VACV) and variola virus, are characterized by a
large linear double-stranded DNA genome (130–300 kb)
packaged in a relatively large virion (;350 3 270 nm),
and a cytoplasmic site of replication (reviewed by Moss,
1996). Assembly of VACV virions begins with condensa-
tion of dense granular material into membrane-wrapped
particles called intracellular mature virions (IMV). Recent
findings indicate the IMV are wrapped by a single mem-
brane (Hollingshead et al., 1999) rather than a double
membrane as previously reported. IMV are then envel-
oped in two additional membranes derived from the
trans Golgi to form multiple membrane-wrapped parti-
cles called intracellular enveloped virions (IEV) (Schmelz
et al., 1994). IEV are moved, possibly by actin polymer-
ization (Cudmore et al., 1995), to the cell periphery, where
the outermost membrane fuses with the cell plasma
membrane, exposing a cell-associated enveloped virion
(CEV) (Blasco and Moss, 1991). CEV are released from
the cell as extracellular enveloped virions (EEV), which
play a role in long-range spread of the virus (Payne,
1980). IMV released from disrupted cells and EEV are
both infectious forms of VACV.
To identify potential targets for poxvirus vaccines or1 To whom reprint requests should be addressed. Fax: (301) 619-
439. E-mail: Jay.Hooper@amedd.army.mil.
32therapeutics, we previously generated and characterized
a panel of VACV-specific monoclonal antibodies (MAbs)
(unpublished data). Passive protection experiments in
mice indicated that neutralizing MAbs binding a 29-kDa
protein (e.g., MAb-10F5, MAb-7D11), and nonneutralizing
MAbs binding a 23- to 28-kDa protein (e.g., MAb-1G10)
protected against challenge with VACV (strain WR) (un-
published data). The target of MAb-7D11 was the product
of the L1R gene (Wolffe et al., 1995), and the target of
MAb-1G10 was the product of the A33R gene (Roper et
al., 1996, and personal communication). In this report, the
L1R and A33R gene products will be called L1R and
A33R, respectively. L1R is an essential myristoylated
protein associated with the IMV membrane and is
thought to play a role in IMV attachment or penetration
(Franke et al., 1990; Ravanello et al., 1993; Ichihashi et al.,
1994; Ravanello and Hruby, 1994; Wolffe et al., 1995).
A33R is a nominally nonessential glycosylated/palmi-
tated protein that forms dimers and is incorporated into
the outer membrane of EEV (Payne, 1992; Roper et al.,
1996). A33R is thought to be involved in facilitating direct
cell-to-cell spread via actin-containing microvilli (Roper
et al., 1998). Homologs of L1R and A33R are present in
other orthopoxviruses; between VACV and variola, L1R
identity is 99.6% and A33R is 94.1% (Massung et al.,
1994).
Naked DNA vaccines have been used to generate
protective immune responses against numerous patho-
genic agents, including many viruses (Gregoriadis,
0042-6822/00 $35.00
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330 HOOPER ET AL.1998). In general, naked DNA vaccines involve vaccina-
tion with plasmid DNA that contains a gene of interest
controlled by a cytomegalovirus (CMV) promoter. When
the plasmid is introduced into mammalian cells, cell
machinery transcribes and translates the gene. The ex-
pressed protein (immunogen) is then presented to the
immune system where it can elicit an immune response.
One method of introducing DNA into cells is by using a
gene gun. This method of vaccination involves using
pressurized helium gas to accelerate DNA-coated gold
beads into the skin of the vaccinee.
To determine whether vaccination with the L1R and/or
A33R gene could elicit protective immunity, we con-
structed plasmids expressing either L1R or A33R under
control of the CMV promoter and tested these plasmids,
and combinations of these plasmids, for immunogenicity
and protective efficacy in mice. Our results indicated that
vaccination with both L1R and A33R proteins, when
loaded on different gold beads and hence delivered to
different cells, was more effective than vaccination with
either protein by itself.
RESULTS
Cloning the vaccinia A33R and L1R genes into
a naked-DNA vector and transient expression
in cell culture
The A33R and L1R genes from VACV (Connaught vac-
cine strain) were PCR amplified and cloned into a naked-
DNA expression vector pWRG7077 (Schmaljohn et al.,
997) to yield constructs pWRG/A33R and pWRG/L1R,
espectively (Fig. 1). Sequence analysis of the L1R and
33R clones indicated that the Connaught strain and WR
train genes are identical at the amino acid level.
To determine whether the appropriate gene products
ere expressed, pWRG/L1R or pWRG/A33R were trans-
ected into COS cells, and radiolabeled proteins were
mmunoprecipitated with MAbs specific to each protein.
Ab-1G10 (A33R-specific) immunoprecipitated a product
ith an apparent size of 23–28 kDa under reducing
onditions and 55 kDa under nonreducing conditions
Fig. 1B). MAb-10F5 (L1R-specific) immunoprecipitated
roducts with apparent sizes of 25 and 29 kDa under
educing and nonreducing conditions (Fig. 1C). Under
educing conditions, the predominant product ran at an
pparent size of 29 kDa, and under nonreducing condi-
ions, the predominant product ran at an apparent size of
5 kDa. Thus both pWRG/A33R and pWRG/L1R ex-
ressed proteins that were bound by A33R- and L1R-
pecific MAbs and had predicted electrophoretic mobil-
ties.
accination with pWRG/L1R elicits neutralizing
ntibody responses in miceTo determine whether vaccination with pWRG/L1R or
WRG/A33R elicited antibody responses in mice, groupsof 9–10 mice were vaccinated with pWRG/L1R, pWRG/
A33R, a combination of pWRG/L1R and pWRG/A33R on
the same gold beads (pWRG/L1R1pWRG/A33R[same
gold]), or a negative control plasmid (pWRG7077) (Exper-
iment 1, Table 1). As positive controls, 10 mice were
vaccinated by tail scarification with VACV (Connaught
strain). Sera were collected before initial vaccinations
(prebleed) and 12 weeks after the final boost.
To measure L1R-specific antibody responses, we per-
formed plaque-reduction neutralization tests (PRNT). All
10 mice vaccinated with pWRG/L1R produced VACV-
specific neutralizing antibodies exhibiting PRNT titers
ranging from 80 to 320, geometric mean titer (GMT) 5
197. Likewise, all 10 mice scarified with VACV produced
neutralizing antibodies with titers ranging from 80 to
1280, GMT 5 368. VACV neutralizing antibodies were not
detected in prebleeds or in sera from mice vaccinated
with either pWRG/A33R or pWRG7077. Interestingly, neu-
tralizing antibodies were not detected in any of nine mice
vaccinated with pWRG/L1R1pWRG/A33R[same gold].
Mean PRNT values for vaccinated mice sera, and control
antibodies are shown (Fig. 2). Thus a neutralizing anti-
body response was elicited when mice were vaccinated
with pWRG/L1R but not when pWRG/L1R was combined
on the same gold beads as pWRG/A33R.
Vaccination with pWRG/A33R elicits antibody
responses in mice
To measure A33R-specific antibody responses, we
developed an ELISA that uses a fixed cell monolayer,
previously transfected with pWRG/A33R, as the solid-
phase antigen. This ELISA is based on the observation
that cells transfected with the A33R gene, or infected
with VACV, exhibit a strong signal when immunostained
with A33R-specific MAbs (Roper et al., 1996). All 10 mice
vaccinated with pWRG/A33R exhibited an anti-A33R an-
tibody response with titers ranging from 400 to 6400,
GMT 5 1600. Similarly, nine of nine mice vaccinated with
pWRG/A33R1pWRG/L1R[same gold] exhibited an anti-
A33R antibody response with titers ranging from 800 to
3200, GMT 5 2352. Only 4 of 10 scarified mice exhibited
detectable anti-A33R antibody responses with titers
ranging from 200 to 800, GMT 5 174. Mean ELISA values
for vaccinated mice and control antibodies are shown
(Fig. 3). Positive control antibodies, MAb-1G10 and VACV
HMAF, had titers of 6400 and 1600, respectively. A sec-
ond anti-A33R antibody, MAb-10F10, had a titer of 3200.
Thus vaccination with pWRG/A33R alone or in combina-
tion with pWRG/L1R elicited a nonneutralizing antibody
response in mice that was significantly greater than the
anti-A33R response elicited by tail scarification with live
VACV. This result was reproduced in three separate ex-
periments (data not shown). Moreover, although an anti-
L1R response was undetected in mice vaccinated with
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331DNA VACCINATION WITH VACCINIA GENESFIG. 1. Naked DNA constructs expressing VACV L1R or A33R genes. (A) The L1R and A33R genes from VACV (Connaught strain) were PCR-amplified
and cloned into a naked DNA expression vector pWRG7077 to yield constructs pWRG/L1R and pWRG/A33R, respectively. The VACV genes are flanked
by a cytomegalovirus immediate early promoter (CMV IE) and intron A at the 59 end of the gene and a bovine growth hormone polyadenylation signal
BGH pA) at the 39 end. Kanamycin antibiotic resistance gene (KAN). (B) Expression products from COS cell monolayers transfected with pWRG/A33R,
r mock transfected, were immunoprecipitated with MAb-1G10. Samples were boiled in reducing or nonreducing sample buffer, and separated by
DS–PAGE. (C) Expression products from COS cell monolayers transfected with pWRG/L1R, or mock transfected, were immunoprecipitated with the
1R-specific antibody MAb-10F5. Samples were boiled in reducing or nonreducing sample buffer, and separated by SDS–PAGE. Molecular mass
arkers in kDa are shown at right of each gel.
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332 HOOPER ET AL.pWRG/L1R1pWRG/A33R[same gold] (Fig. 2), a robust
anti-A33R response was detected (Fig. 3).
Protection against lethal infection after vaccination
with pWRG/L1R and/or pWRG/A33R
To test whether pWRG/L1R and/or pWRG/A33R could
protect mice from lethal challenge with VACV, mice were
T
Vaccination Schedule
Experiment Group Immunogen
1 (2)controla
pWRG/L1R
pWRG/A33R
pWRG/L1R1pWRG/A33R[same gold]
Scarificationb
2 1 (2)controla
2 pWRG/L1R
3 pWRG/A33R
4 pWRG/L1R1pWRG/A33R[same gold]
5 pWRG/L1R1(2)control[same gold]
6 pWRG/A33R1(2)control[same gold]
7 pWRG/L1R1pWRG/A33R[different
gold]
8 pWRG/L1R1(2)control[different gold]
9 pWRG/A33R1(2)control[different gold]
10 Scarificationb
Note. NA, not applicable.
a (2)control, negative control plasmid.
b VACV (Connaught strain) (10 ml drop of PBS containing 8 3 106 PF
FIG. 2. VACV-neutralizing antibody response elicited by gene gun v
WRG/L1R, or 10 mice scarified with VACV are shown. Also shown ar
WRG/A33R plus pWRG/L1R combined on the same gold beads, or a negativ
Ab-7D11 and VACV HMAF, are also shown.vaccinated with a single construct or both constructs and
then challenged with a lethal dose of VACV. Dual con-
struct vaccinations were performed with either a combi-
nation of both plasmids on the same gold beads or gold
beads coated with individual constructs. The vaccination
schedule of Experiment 2 is shown in Table 1.
Most mice vaccinated with pWRG/L1R developed neu-
ne Gun Experiments
per
ridge
g)
Number of
cartridges
per dose
Boost 1
(wks after
priming)
Boost 2
(wks after
boost 2)
Final bleed
(wks after
final boost)
.5 2 4 4 12
.5 2 4 4 12
.5 2 4 4 12
each 2 4 4 12
A NA NA NA 12
.5 2 3 2 2
.5 2 3 2 2
.5 2 3 2 2
each 2 3 2 2
each 2 3 2 2
each 2 3 2 2
.5 1 each 3 2 2
.5 1 each 3 2 2
.5 1 each 3 2 2
A NA NA NA 2
tched into tail ;1 cm from base) as positive controls.
tion with pWRG/L1R. Mean PRNT values of 10 mice vaccinated with
ean PRNT values of groups of 10 mice vaccinated with pWRG/A33R,ABLE 1
s of Ge
DNA
cart
(m
0
0
0
0.5
N
0
0
0
0.5
0.5
0.5
0
0
0
Naccina
e the me control plasmid. Titrations of postitive control antibody ascitic fluid,
t twofold
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333DNA VACCINATION WITH VACCINIA GENEStralizing antibodies (Groups 2, 5, 7, and 8; Fig. 4); how-
ever, as in Experiment 1, if pWRG/A33R was combined on
the same gold beads with pWRG/L1R, none of the mice
developed neutralizing antibodies (Group 4, Fig. 4). Most
mice vaccinated with pWRG/A33R developed anti-A33R
antibodies regardless of whether pWRG/L1R was
present on the same gold beads (Groups 3, 4, 6, 7, and 9;
Fig. 4). All of the scarified mice developed neutralizing
antibodies, which represent not only anti-L1R antibodies
but also antibodies to other neutralizing antigens. Only
one scarified mouse in Experiment 2 had an anti-A33R
titer $200 (Group 10, Fig. 4).
Two weeks after the final vaccination, mice were chal-
lenged intraperitoneally (i.p.) with 5 3 108 PFU (12.5 LD50)
of VACV WR. The results of the protection experiment are
shown in Figs. 4 and 5. All mice vaccinated by tail
scarification survived challenge with minimal clinical
signs of disease except a transient weight loss (Fig. 5).
All mice vaccinated with the negative control plasmid
died within 3 days (Fig. 5A). Most mice vaccinated with
pWRG/L1R alone (Group 2), or combined with a negative
control plasmid, on the same or different gold (Groups 5
and 8), survived challenge, suggesting vaccination with
pWRG/L1R provided partial protection against an i.p.
challenge with VACV WR. In most cases, the L1R-vacci-
nated mice that succumbed did so at later times after
challenge than controls (Fig. 5A). Although seven of nine
mice vaccinated with pWRG/A33R alone survived chal-
lenge (Group 3), none of the mice vaccinated with pWRG/
A33R combined with a negative control plasmid, on the
same or different gold, survived challenge (Groups 6 and
FIG. 3. Anti-A33R antibody response elicited by gene gun vaccination
ransfected with pWRG/A33R were fixed and then incubated with serial
accinated with the indicated immunogen and titrations of postitive co9). Mice vaccinated with pWRG/A33R alone, that sur-
vived challenge, exhibited sustained morbidity (a greaterthan 10% reduction in body weight on Days 2–5 post
challenge) (Fig. 5B). In a follow-up experiment performed
to further examine the protective efficacy of vaccination
with pWRG/A33R alone, 10 of 10 mice died within 4 days
despite having anti-A33R antibody titers comparable to
those in Group 3, Fig. 4 (data not shown). Together these
data suggest that vaccination with A33R provided mini-
mal protection against i.p. challenge with VACV WR and
was not an effective vaccine against i.p. challenge.
When mice were vaccinated with both plasmids, the
results differed dramatically depending on whether the
plasmids were loaded on the same or different gold
beads. When pWRG/A33R and pWRG/L1R were com-
bined on the same gold beads, all but one of the mice
died (Group 4). In contrast, when the plasmids were
loaded on different gold beads all of the mice were
protected (Group 7). Morbidity, as measured by weight
loss, was similar in the scarified mice and the mice
vaccinated with pWRG/L1R1pWRG/A33R[different gold]
(Fig. 5B).
DISCUSSION
The smallpox vaccine, i.e., scarification with VACV, is
one of the oldest and most successful vaccines ever
developed. A sustained worldwide vaccination program
resulted in the eradication of naturally occurring small-
pox disease in 1979. However, elimination of smallpox
has not eliminated the need for a poxvirus vaccine
and/or other anti-poxvirus measures such as vaccinia
immunglobulin (VIG) because other pathogenic poxvi-
WRG/A33R. To measure the anti-A33R response, COS cell monolayers
dilutions of serum or control antibodies. Mean O.D. values of 10 mice
ntibody ascitic fluid, MAb-1G10 and VACV HMAF, are shown.with pruses (e.g., monkeypox virus) and bioterrorism remain a
threat (Breman and Henderson, 1998). We are interested
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FIG. 4. Prechallenge antibody titers and survival data. Sera from mice
ctivity by PRNT, and for anti-A33R activity by ELISA. Sera were collec
n each group are shown. Filled bars represent animals that did not su
ice (Group 10), the PRNT values represent all VACV neutralizing an
esponses were detected, geometric mean titers (GMT) are shown. Nas naked DNA constructs could provide protection
against poxvirus infection (i.e., replace VACV scarifica-tion) and/or serve as immunogen for the generation of
ated as described in Table 1, Experiment 2, were evaluated for anti-L1R
ediately before challenge. PRNT and ELISA titers for individual mice
allenge, and cross-hatched bars represent survivors. For the scarified
s, not just the anti-L1R response. In groups where positive antibody
ested.vaccin
ted imm
rvive ch
tibodieprotective monoclonal antibodies (i.e., replace VIG).
Of the ;200 genes that comprise the vaccinia ge-
o ps 2, 3
g ded fro
335DNA VACCINATION WITH VACCINIA GENESnome, only 5 encode proteins that are known to elicit a
FIG. 5. Protection experiment. Vaccinated animals (see Experiment 2
LD50). (A) The number of survivors each day after challenge are shown. (
f starting weight was calculated. Mean weight values for mice in Grou
roup, animals with the highest and lowest weight change were excluneutralizing antibody response including: H5R (Gordon
et al., 1991), A27L (Rodriguez and Esteban 1987; Lai et al.,1991), B5R (Galmiche et al., 1999), D8L (Hsiao et al.,
1 and Fig. 4) were challenged i.p. with 5 3 108 PFU of VACV WR (12.5
were weighed at the indicated day postchallenge and the percentage
, 7, and 10, that ultimately survived the challenge, are shown. For each
m the calculations., Table
B) Mice1999), and L1R (Ichihashi et al., 1994; Wolffe et al., 1995).
Given the structural complexity of VACV, there may be
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336 HOOPER ET AL.other neutralizing antigens not yet identified. In addition,
the A33R gene encodes a protein that elicits a nonneu-
tralizing antibody response that is, nevertheless, protec-
tive (Galmiche et al., 1999; Schmaljohn, unpublished
ata). Two core proteins (A10L and A4L) demonstrate
ome protective immunity; however, it is unclear if the
mmunity is humoral or cell-mediated (Demkowicz et al.,
992). As a first step toward determining if a combination
f vaccinia proteins could provide the basis for an alter-
ative poxvirus vaccine or VIG, we evaluated the immu-
ogenicity and protective efficacy of two gene products
hat are found either on the IMV or EEV.
1R
Our results show that vaccination with the L1R gene
an elicit neutralizing antibodies and provide protection
gainst lethal poxvirus infection. We found that the
onospecific neutralizing antibody titers elicited by vac-
ination with L1R were only twofold lower than the poly-
lonal neutralizing antibody response generated by tail
carification with VACV. We suspect that modification of
ur construct or vaccination procedure may allow us to
ncrease the anti-L1R neutralizing antibody titer several-
old. This optimism is based on the fact that L1R-specific
Abs are extremely potent [PRNT50% titer of MAb-7D11
ascitic fluid is 1025 g/l (Wolffe et al., 1995)].
The virus used in our challenge experiments was
derived from infected cell lysates, and therefore consists
primarily of IMV. Because L1R is found on the surface of
IMV, it is likely that L1R vaccination confers protection by
eliciting neutralizing antibodies that reduce the effective
virus challenge well below 1 LD50. It remains unclear if
nti-L1R antibodies play a role in preventing dissemina-
ion of virus from infected cells after establishment of
nfection. The observation that MAb-7D11 failed to pre-
ent plaque formation in vitro when added to cells after
nfection (unpublished data) suggests that L1R-specific
eutralization involves inhibition of an early step in in-
ection (e.g., attachment or penetration) and not cell-to-
ell spread. This is not surprising because the forms of
irus most prominent in cell-to-cell spread, CEV and EEV
Payne, 1980), are inaccessible to anti-L1R antibodies,
hich neutralize the IMV form of virus (Wolffe et al., 1995;
Ichihashi et al., 1994). It is conceivable that L1R-specific
neutralizing antibodies play a role in vivo by neutralizing
IMV released from infected cells (by immune mecha-
nisms or by virus-induced cell lysis). We have not inves-
tigated the possibility that vaccination with L1R elicits a
cell-mediated immune response that contributes to pro-
tective immunity.
A33R
Based on our earlier passive protection studies of
MAbs specific to A33R, we suspected that vaccination
with a naked DNA construct expressing the A33R prod-
b
tuct might confer protection. The experiments reported
here, and those recently reported by others (Galmiche et
al.,1999), confirmed that vaccination with the A33R gene
does provide some protection against VACV. Galmiche et
al. found that vaccination of mice with purified baculovi-
rus expressed A33R protein, or a naked DNA construct
expressing A33R, protected against a lethal intranasal
(i.n.) VACV (strain IHD-J) challenge (Galmiche et al.,1999).
In addition, Galmiche et al. found that passive transfer of
serum from A33R vaccinated mice, but not rabbits, could
passively protect mice against i.n. challenge. We previ-
ously found that A33R-specific monoclonal antibodies
(e.g., MAb-1G10) plus complement lysed VACV-infected
cells (Schmaljohn, unpublished data). Together these
findings suggest that vaccination with A33R elicits anti-
bodies that provide a degree of protection by directing
the lysis of VACV-infected cells. In our challenge model,
i.p. challenge with VACV WR, vaccination with A33R
alone protected some mice in one experiment (Group 3
in Figs. 4 and 5); however, only 1 of 10 mice was pro-
tected when A33R was combined with L1R on the same
gold beads, and none of the mice vaccinated with A33R
combined with a negative control plasmid were pro-
tected despite relatively high anti-A33R antibody titers.
Also, in a follow-up experiment designed to reexamine
the protective efficacy of A33R, all 10 mice vaccinated
with pWRG/A33R alone died within 4 days after i.p. chal-
lenge. These data suggest that an anti-A33R response
fails to confer a consistent level of protection against an
i.p. challenge with VACV WR.
It seems likely that an immune response to A33R plays
a role principally in reducing the dissemination of virus
or the yield of infectious virions per cell not in preventing
primary infection. Failure of vaccination with A33R to
consistently protect mice from an i.p. challenge might
indicate that the initial infection is itself lethal or levels of
disseminating progeny virus produced after challenge
with 5 3 108 PFU overwhelm the anti-A33R immune
response. On the other hand, vaccination with A33R may
protect against a smaller challenge dose that requires
more dissemination for lethality, such as the i.n. route of
challenge used by Galmiche et al. (105–6 PFU of the IHD-J
train of VACV) (Galmiche et al., 1999).
1R1A33R[same gold]
Although mice vaccinated with both L1R and A33R on
he same gold beads had anti-A33R responses equiva-
ent to those given only A33R, neutralizing antibodies
ere not detected. To our knowledge, this is the first
escription of one DNA vaccine immunogen suppress-
ng the antibody response to a codelivered immunogen.
his result was not due to a technical problem in coload-
ng two plasmid preparations on the same gold beads
ecause both plasmids could be eluted from the car-
ridges used to vaccinate the mice (data not shown). In
337DNA VACCINATION WITH VACCINIA GENESaddition, this result was not due to A33R- and L1R-
specific antibody interaction (e.g., A33R-specific antibod-
ies sterically interfering with binding of L1R-specific an-
tibodies) because mice vaccinated with L1R and A33R
on different gold exhibited high titers of both A33R-
specific antibodies and neutralizing antibodies (presum-
ably L1R-specific). Although there was no evidence that
A33R affects L1R immunogenicity in VACV-infected cells,
it is possible that A33R downregulated translation or
processing of L1R in plasmid-transfected cells by direct
or indirect interactions and in doing so suppressed L1R
immunogenicity. Another possible explanation for our
results is that A33R-specific antibodies, elicited during
the first vaccination, may have directed lysis of A33R-
expressing cells during subsequent boosts and, in doing
so, diminished the boosting effect. This hypothesis pre-
dicts that immunogens that require boosts to elicit de-
tectable immune responses may be adversely affected
by codelivery of pWRG/A33R. Consistent with this hy-
pothesis, neutralizing antibodies to VACV were not de-
tected after a single vaccination with pWRG/L1R (data
not shown), indicating boosts are required for a detect-
able anti-L1R response. It remains to be determined if
pWRG/A33R can inhibit immune responses to other co-
delivered immunogens.
L1R1A33R[different gold]
Vaccination with L1R and A33R administered on dif-
ferent gold beads, and therefore delivered to different
cells, resulted in a greater level of protection than either
immunogen alone. Mice vaccinated with both immuno-
gens appeared to be protected almost as well as the
scarified mice. Our working hypothesis is that L1R-spe-
cific antibodies limit the initial infection by neutralizing
challenge virus (which is predominantly IMV), and A33R-
specific antibodies are involved in preventing EEV dis-
semination by eliminating EEV or infected cells (e.g., via
antibody-dependent cell-mediated cytotoxicity or anti-
body-dependent complement-mediated cytotoxicity). Ly-
sis of infected cells may result in release of IMV and, in
the absence of IMV neutralizing antibodies, may allow
IMV-mediated dissemination.
The challenge model used here, WR strain of VACV
administered to mice by the i.p. route, has been used
previously to assess the protective efficacy of vaccina-
tion with individual VACV immunogens (Demkowitz et al.,
1992). We used this model to demonstrate that vaccina-
tion with L1R and A33R provides protection; however,
because this is one vaccination protocol, one challenge
virus, and one route of challenge, it will be important to
evaluate the protective efficacy of these immunogens in
other challenge models that use different viruses (e.g.,
other virulent VACV strains such as the IHD-J strain or
other poxviruses such as monkeypox virus), different
routes of administration (e.g., i.n. or aerosol routes), ordifferent susceptible animal species (e.g., monkeys). It
also will be necessary to optimize vaccine formulations
and vaccination schedules. Information derived from al-
ternative vaccine protocols and challenge models should
help us better predict whether or not a combination of
poxvirus immunogens (e.g., L1R and A33R), as a vaccine
or source of immunoglobulin, might confer protection in
humans.
In summary, in this study we demonstrated that vac-
cination of mice with VACV genes encoding proteins
found on the surface of two infectious forms of the virus
(L1R found on the IMV and A33R found on the EEV)
provide a greater level of protection than vaccination
with either gene alone. By combining additional VACV
immunogens with LlR and A33R, it may be possible to
develop a vaccine that elicits an even more potent and
redundant anti-poxvirus immune response. These stud-
ies should also help identify targets for the rational de-
sign of a monoclonal antibody-based replacement for
VIG.
MATERIALS AND METHODS
Viruses and cells
VACV Connaught vaccine strain (derived from the New
York City Board of Health strain) (McClain et al., 1997)
and strain WR (Western Reserve)( ATCC VR-119) were
maintained in VERO cell (ATCC CRL-1587) monolayers
grown in Eagle minimal essential medium, containing 5%
heat-inactivated fetal bovine serum, 1% antibiotics (100
U/ml penicillin, 100 mg/ml streptomycin, and 50 mg/ml
gentamicin), 10 mM HEPES (cEMEM)s. COS cells (ATCC
CRL 1651) were used for transient expression experi-
ments.
Antibodies
Two L1R-specific (MAb-7D11 and MAb-10F5) and two
A33R-specific (MAb-1G10 and MAb-10F10) MAbs, as
mouse ascitic fluids, were used. VACV (strain Con-
naught) hyperimmune mouse ascitic fluid (VACV HMAF)
was also used.
Cloning L1R and A33R into naked-DNA expression
plasmids
VACV (Connaught strain) DNA was purified by stan-
dard methods and used as template for PCR and cloning
of the L1R and A33R genes. PCR primer design was
based on the published VACV (Copenhagen strain) se-
quence (accession number M35027). The L1R primers
were: 59-gccgcggccgcatggtgccgcagcaagcatacag and
59-gccggcggccgctcagttttgcatatccgtggtag; and the A33R
primers were: 59-gccggcggccgcatgatgacaccagaaa-
acgacg and 59-gccggcggccgcttagttcattgttttaacaca. NotI
sites (underlined) were incorporated at gene termini.
Start codons are shown in bold. L1R and A33R were
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338 HOOPER ET AL.PCR-amplified using VENT polymerase (NEB), cut with
NotI, and cloned into the NotI site of plasmid pWRG7077
(Schmaljohn et al., 1997) to yield naked DNA expression
lasmids pWRG/L1R and pWRG/A33R, respectively.
ransient expression
Plasmid DNA was transfected into COS cell monolay-
rs (60–80% confluent) using Lipofectin or Fugene6 re-
gent as described by the manufacturer. After 24–48 h,
onolayers were radiolabeled with Promix (200 mCi per
-25 flask, [35S]methionine and [35S]cysteine; Amersham)
nd immunoprecipitated as follows. Transfected cells
ere lysed on ice for 5 min with a modified RIPA buffer:
.25 M NaCl, 1 mM EDTA, 1% Triton X-100, 0.5% sodium
eoxycholate, 10 mM Tris, pH 7.4, and protease inhibitors
Complete; Boehringer Mannheim). To increase the yield
f precipitable L1R, 10 mM iodoacetamide was included
n the lysis buffer (Wolffe et al., 1995). Lysates were
ombined with the indicated antibody (previously incu-
ated with unlabeled COS cell lysate) and incubated
vernight at 4°C. Lysate-antibody mixtures were com-
ined with protein A sepharose (CL-4B; Sigma), incu-
ated at 4°C for 30 min, and then washed three times
ith lysis buffer and once with 10 mM Tris, pH 8.0.
ample buffer [125 mM Tris (pH 8.0), 1% SDS, 10% glyc-
rol, 0.01% bromphenol blue containing 2% 2-mercapto-
thanol for reducing gels or 10 mM iodoacetamide for
onreducing gels] was added and the samples were
oiled for 2 min. Samples were then analyzed by sodium
odecyl sulfate(SDS)–10% polyacrylamide gel electro-
oresis (PAGE) and subjected to autoradiography.
accination with the gene gun
Cartridges for the gene gun were prepared as de-
cribed previously (Eisenbraun et al., 1993; Schmaljohn
t al., 1997). Briefly, plasmid DNA was precipitated onto
2 mm diameter gold beads (Degussa), 1 mg DNA per 1
mg gold, which were then coated on the inner surface of
Tefzel tubing (McMaster-Carr). The tubing was cut into
0.5-in cartridges. When completed, each cartridge con-
tained 0.25–0.5 mg of DNA coated on 0.5 mg of gold. To
vaccinate animals, abdominal fur was removed with clip-
pers and DNA-coated gold was administered to two
nonoverlapping sites on the abdominal epidermis by
using the gene gun (Powderject Delivery Device, Pow-
derject, Inc.) at 400 p.s.i. as described previously (Pert-
mer et al., 1995).
Plaque reduction neutralization assay
VACV-infected cell lysate was diluted in cEMEM to
give ;1000 PFU/ml. Aliquots of this virus suspension
(100 ml) were incubated with an equal volume of antibody
diluted in cEMEM (serum samples were heat inactivated,
56°C for 30 min, prior to dilution) for 1 h at 37°C and then
180 ml of sample was adsorbed to VERO cell monolayersin 6-well plates (or 12-well plates) for 1 h. A 2 ml cEMEM
liquid overlay was added to each well (1 ml for 12-swell
plates). After 3 days at 37°C, monolayers were stained
with 1% crystal violet dissolved in 70% ethanol. Plaques
were counted and the percent neutralization was calcu-
lated relative to plaque numbers in the absence of anti-
body. Titers represent the reciprocal of the highest dilu-
tion resulting in a 50% reduction in the number of
plaques.
Transfection/ELISA method
COS cell monolayers, grown in 96-well cell culture
plates, were transfected with pWRG/A33R (0.2 mg/well)
using Fugene6 or were mock transfected. After ;24 h
the monolayers were fixed with 1:1 acetone:methanol for
2 min and immunostained as previously described
(Roper et al., 1996); however, the dianisidine substrate
was replaced with 2,29-azino-bis(3-ethylbenzthiazoline-6-
sulfonic acid (ABTS) substrate. Briefly, monolayers were
fixed with 1:1 acetone:methanol for 2 min, rinsed with
PBS, incubated 1 h with primary antibody diluted in
PBS13%FBS, rinsed with PBS, incubated 30 min with
peroxidase-labeled goat anti-mouse antibody (Sigma) di-
luted in PBS13%FBS, rinsed, and finally, incubated with
ABTS. After ;30 min, 100 ml per well of 0.2 N phosphoric
acid was added and the O.D. at 405 nm was determined
by an ELISA plate reader. O.D. values from mock-trans-
fected wells were subtracted from those of transfected
wells to determine the specific O.D. 405 nm for each
sample. End-point titers were determined as the highest
dilution with an absorbence value greater than the mean
absorbence value from negative control plasmid
(pWRG7077)-vaccinated animals plus three standard de-
viations.
Challenge experiment
Mice were injected with 5 3 108 PFU of VACV strain
R (12.5 LD50) (clarified infected cell lysate) by the intra-
peritoneal route (i.p.) with a 0.5 3 16 mm needle. This
esearch was conducted in accordance with procedures
escribed in the Guide for the Care and Use of Labora-
ory Animals (National Institute of Health, 1996). The
acilities are fully accredited by the American Associa-
ion for Accreditation of Laboratory Animal Care.
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